Terumo BCT Acquires GADA Turkey

  Terumo BCT Acquires GADA Turkey

Turkish medical products and services distributor provides strategic benefits

Business Wire

LAKEWOOD, Colo. -- November 4, 2013

Terumo BCT has acquired GADA^® Turkey, an exclusive supplier and world-class
distributor of blood bank components and equipment to Turkish public and
private healthcare facilities.

GADA Turkey has been a Terumo BCT distributor to blood banks and hospitals
since 2009. The acquisition provides Terumo BCT with a direct relationship
with Turkish blood banks and the ability to drive further adoption of critical
blood transfusion technologies that can improve the safety and quality of
blood in Turkey. The acquisition will also enable hospitals to have expanded
access to Terumo BCT’s therapeutic aphaeresis technologies.


  *Prior to the acquisition, GADA Turkey was a subsidiary of The GADA^® Group
    Holding, a United Kingdom-based, leading pan-European, distributor of
    specialized medical technology devices and equipment and a provider of
    health care services supplies and integrated project to public and private
  *GADA Turkey is active in two major segments: blood technologies and
    general hospital.

       *The blood technologies segment is composed of three different areas:
         blood banking, transfusion and therapeutics.
       *The general hospital segment focuses on a wide-choice supply of high
         technology single-use devices and disposables.


Vincent Gaspar, Senior Vice President and General Manager, EMEA, Terumo BCT

“Strategically the GADA Group is a great fit. It is a well-run company with a
strong reputation for customer service, quality and collaboration. With this
acquisition we will expand our presence in Turkey and the success we have had
with our automated collection and therapeutic aphaeresis products. We also
intend to introduce Whole Blood Automation and our Mirasol^® blood safety
products in the Turkish market. We look forward to continuing the high level
of support to our customers with field-based resources, and to providing them
with direct access to our wide range of products and services.”

About Terumo BCT:

Terumo BCT, a global leader in blood component, therapeutic aphaeresis and
cellular technologies, is the only company with the unique combination of
aphaeresis collections, manual and automated whole blood processing, and
pathogen reduction coupled with leading technologies in therapeutic aphaeresis
and cell processing. We believe in the potential of blood to do even more for
patients than it does today. This belief inspires our innovation and
strengthens our collaboration with customers.

Principal Terms and Closing:

The transaction has been structured as a share purchase and is expected to
close in Terumo BCT’s fourth fiscal quarter, subject to approval and customary
conditions. After the closing, GADA Turkey will be operated as a subsidiary of
Terumo BCT Europe, N.V.

Special Note:

Statements that relate to future results and events are forward-looking
statements based on Terumo BCT’s and the GADA Group’s current expectations.
Actual results and events in future periods may differ materially from those
expressed or implied by these forward-looking statements because of a number
of risks, uncertainties and other factors. Risks, uncertainties and
assumptions include the possibility that projected benefits may not
materialize as expected; that the transaction may not be timely completed, if
at all; that Terumo BCT and the GADA Group are unable to successfully
implement the plans, strategies and objectives of management for future


Terumo BCT
Laura Fusco, +1-303-205-2546
Global Corporate Communications
Press spacebar to pause and continue. Press esc to stop.